Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients
The primary aim of this study is to evaluate a novel point-of-care (POC) lateral flow assay for the diagnosis of neurocysticercosis (NCC). The study is being led by a Boston-based biotechnology company that has developed a rapid blood test to screen patients presenting with seizures in order to distinguish those with NCC from those with idiopathic epilepsy or other conditions, leading to faster identification and treatment of patients with NCC.
Location: United States of America; Peru
